Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Phase II trial of mitoxantrone in advanced sarcomas: a Southwest Oncology Group study.

× No keyword cloud information.

8 in total

1. Systematic therapy for unresectable or metastatic soft-tissue sarcomas: past, present, and future.

Authors: Sherif S Morgan; Lee D Cranmer
Journal: Curr Oncol Rep Date: 2011-08 Impact factor: 5.075

2. Leiomyosarcoma of the great saphenous vein.

Authors: Y Saglik; F Icli; O Uluoglu; Z U Isiklar
Journal: Int Orthop Date: 1992 Impact factor: 3.075

3. Effectiveness of mitoxantrone on the proliferation of cell cultures derived from malignant mesenchymal tumors of human origin.

Authors: M Dietel; H Arps; D Gerding; M Trapp; M Sieck; A Niendorf
Journal: J Cancer Res Clin Oncol Date: 1988 Impact factor: 4.553

Review 4. Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors: D Faulds; J A Balfour; P Chrisp; H D Langtry
Journal: Drugs Date: 1991-03 Impact factor: 9.546

5. Enhanced Antitumor Efficacy of PhAc-ALGP-Dox, an Enzyme-Activated Doxorubicin Prodrug, in a Panel of THOP1-Expressing Patient-Derived Xenografts of Soft Tissue Sarcoma.

Authors: Britt Van Renterghem; Agnieszka Wozniak; Ludovica Tarantola; Andrea Casazza; Jasmien Wellens; Madita Nysen; Ulla Vanleeuw; Che-Jui Lee; Geert Reyns; Raf Sciot; Nele Kindt; Patrick Schöffski
Journal: Biomedicines Date: 2022-04-06

6. Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas.

Authors: Elisa Stroppa; Alexia Bertuzzi; Gabriele Di Comite; Chiara Mussi; Romano Fabio Lutman; Alfredo Barbato; Armando Santoro
Journal: Invest New Drugs Date: 2009-07-07 Impact factor: 3.850

7. High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group.

Authors: O S Nielsen; P Dombernowsky; H Mouridsen; D Crowther; J Verweij; J Buesa; W Steward; S Daugaard; M van Glabbeke; A Kirkpatrick; T Tursz
Journal: Br J Cancer Date: 1998-12 Impact factor: 7.640

8. Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas.The Experience of the EORTC Soft Tissue and Bone Sarcoma Group.

Authors: O S Nielsen; P Dombernowsky; H Mouridsen; S Daugaard; M Van Glabbeke; A Kirkpatrick; J Verweij
Journal: Sarcoma Date: 2000

8 in total